FDA 483 - Llorens Pharmaceuticals International Division, Inc. - May 15, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Llorens Pharmaceuticals International Division, Inc. in Miami, FL, an OTC drug and dietary supplement manufacturer, revealed two significant observations. The firm's stability program for drug products lacked reliable test methods, specifically failing to perform force degradation studies on OTC products. Additionally, the Quality Unit did not fully follow established procedures for sampling and testing purified water, including documentation of water discarding times.
- Inspection Date
- May 15, 2025
- Product Type
- Drugs
- Office
- Florida District Office
- Person
ID · 4daca291-097a-41f3-b7cc-d68bc7da5ee1